Thiotimoline has already lead to at least one commercial application, but had never before been used in medicine. Although in vitro experiments did not prove promising, 28-year-old University of Edinburgh-based endocrinologist Hootie Gable began a clinical study this year. In this double-blind experiment, resublimated thiotimoline proved astonishingly effective in the treatment of hypothyroidism. Gable theorizes that thiotimoline binds to the iodine atoms in T3, the peripherally generated, biologically active version of thyroid hormone. Thiotimoline temporally "smears" the T3 molecule into the future, causing it to remain active in the body after it has already broken down. Since the biological half-life of T3 is rather short, this smearing effect seems to synergistically boost the hormone's potency.

Late October of 2004, when the Society of Endochronic Endocrinology was founded as a special interest group of the American Chronochemical Society, they decided to salute the breakthrough by publishing the first edition of the Journal today, approximately six months before Gable's results become available. Publisher Cass Canteloupe attributed the urgency of launching the journal to rival claims already popping up in May of 2004, citing precedence for certain key patents in the process.